Quantitative mismatches between human physiology and experimental models can present serious 13 limitations for the development of effective therapeutics. We addressed this issue, in the context of 14 cardiac electrophysiology, through mechanistic mathematical modeling combined with statistical 15
INTRODUCTION 24
While the goal of much biomedical research is to understand human physiology and pathophysiology, 25 direct human experiments are often infeasible and/or unethical. Because of this, experimental models 26 of human physiology are often required. These can include cell culture models and animal models of 27 human disease. To the extent that they provide a reasonable representation of the human system of 28 interest, the experimental models are useful. However, when a behavior or physiological response in the 29 experimental model does not match the behavior or response seen in the target system, the limitations 30 of the experimental model become a concern. These differences may be qualitative; for instance a drug 31 that is efficacious in a mouse model of disease may fail completely at treating the human disease 32 because mice and humans express different isoforms of a protein. Often, however, these differences are 33 quantitative. For example, a diabetes drug may lower blood glucose in both a mouse model and in 34 diabetic patients, but to different extents. 35
A strategy for addressing this issue is to build mathematical frameworks that correct for the limitations 36 of the experimental model. In some cases this is trivial --for instance, the appropriate dose of a drug can 37 often easily be adjusted by a patient's weight. In other cases empirical correction factors can be derived 38 through painstaking trial and error. However, such correction factors generally only apply under specific 39 conditions, and no general method exists to quantitatively correct for the inaccuracies of how an 40 experimental model will respond to a variety of relevant perturbations. 41
An example of considerable immediate importance concerns cardiac electrical activity in myocytes 42 derived from induced pluripotent stem cells (iPSC-CMs). Because these cells are a readily-obtainable and 43 renewable source of human cardiac myocytes, they are gaining popularity as a platform to screen drugs 44 for toxicity testing (Doherty et al., 2015 , Gibson et al., 2014 , Qu & Vargas, 2015 . However, the cells 45 exhibit immature physiology compared with ventricular myocytes from adult hearts (Li et al., 2013, van 46 den Heuvel et al., 2014) , and it remains unclear how well drug tests performed in iPSC-CMs will 47 recapitulate the effects observed in human hearts. 48
We hypothesized that mechanistic, population-based simulations (Britton et al., 2013 , Gemmell et al., 49 2014 , Maltsev & Lakatta, 2013 , Marder, 2011 , Marder & Taylor, 2011 , Sarkar et al., 2012 , Walmsley et 50 al., 2013 could be used to quantitatively map physiological responses between cell types. To test 51 whether this idea was feasible, we attempted to translate drug responses from iPSC-CMs to human 52 adult ventricular myocytes. Beginning with mathematical models of two cell types (O'Hara et al., 2011, 53 Paci et al., 2013), we combined simulations of heterogeneous populations with multivariable regression 54
approaches. The resulting model could be used to predict, with quantitative accuracy, drug effects in 55 human adult myocytes based on recordings in iPSC-CMs. Moreover, we found that the approach could 56 be generalized to quantitatively predict effects in diseased myocytes and across multiple species. This 57 strategy is not only practically useful to address contemporary problems in drug development, it 58 provides a framework for addressing the vexing question of experimental model limitations. 59
RESULTS 60
Human iPSC-CMs and adult myocytes exhibit quantitative differences in their responses to ionic 61 current perturbations 62 We performed simulations to understand differences between iPSC-CMs and human adult myocytes in 63 the electrophysiological responses to drugs. Fig. 1A and 1B , respectively, show how the two cell types 64 respond to blocking of I Kr and I CaL currents by 25% and 50%. These results demonstrate that the two cell 65 types exhibit differences in baseline action potential (AP) and calcium transient (CaT) morphology, but 66 qualitatively similar responses to ionic current blockade. We quantified the effects of ionic current 67 perturbation by calculating the AP duration at 90% repolarization (APD 90 ) and CaT amplitude (CaTA and transporters that are common to both models, we observed marked differences in how 74 perturbations to these ion transport pathways affected APD 90 and CaTA ( Fig. 1E and 1F ). These 75 differences highlight that drug responses observed in iPSC-CMs will not necessarily match the responses 76 seen to the same drugs in adult myocytes, and a comprehensive method is therefore required to 77 quantitatively translate physiological responses across cell types. 78
A multivariable regression model can translate drug responses across cell types 79
We developed a statistical model, based on principles of multivariable regression ( Fig. 2A ), to predict 80 metrics derived from AP and CaT waveforms in adult myocytes from physiological recordings in iPSC-81
CMs. Heterogeneous in silico populations of 600 cells of each type were generated by randomizing the 82 maximal conductance values for 13 ion transport pathways, and Partial Least Squares Regression (PLSR) 83 (Abdi & Williams, 2013 , Geladi & Kowalski, 1986 , Kreeger, 2013 Table S3 , 93
Supporting Information). 94 (A) Action potential (AP) waveforms simulated in human adult myocyte and iPSC-CM mathematical models before (dashed lines) and after (solid lines) 25% and 50% block of I Kr . (B) Calcium transient (CaT) time courses of the two cell types at baseline (dashed lines), and after 25% and 50% block of I CaL (solid lines). (C, D) Quantification of AP duration at 90% repolarization (APD 90 , C) and CaT amplitude (CaTA, D) as a function of maximal conductances controlling I Kr (G Kr , left) and I CaL (G CaL , right) in adult myocyte (blue) and iPSC-CM (red) models. All variables are expressed as a percentage of the control value obtained in the absence of perturbation. (E, F) Sensitivity coefficients indicating the extent to which perturbations in each ion transport pathway causes changes in APD 90 (E) and CaTA (F). Coefficients are shown for both adult myocyte (blue) and iPSC-CM (red) models.
Figure 2. Regression model to predict adult myocyte responses from iPSC-CM physiology. (A)
Regression strategy for development of a cross-cell type model that maps physiological responses from one cell type (iPSC-CM, left) to another cell type (adult myocyte, right). The resulting regression matrix B cross serves to generate predictions on adult myocyte responses when measurements are made in iPSC-CM following the same perturbations. Insets: Physiological features quantified from iPSC-CM (left) and adult myocyte (right) simulations. AP features (top): (1) AP duration (APD) at -60 mV; (2) APD at 90% repolarization (APD 90 ); (3) APD at 50% repolarization (APD 50 ); (4) peak membrane voltage (V peak ); (5) resting membrane voltage (V rest ). CaT features (bottom): (6) CaT amplitude (CaTA); (7) resting [Ca 2+ ] i (Ca rest ); (8) peak [Ca 2+ ] i (Ca peak ); (9) CaT duration (CaD) at 50% return to baseline (CaD 50 ); (10) CaT decay time; (11) CaT duration (CaD) at 90% return to baseline (CaD 90 ). For simulations of iPSC-CM spontaneous (rather than electrically paced) activity, the beating frequency was also quantified and included in the regression model. Experimental protocols that alter ionic concentrations provide critical information for the regression 95 model 96 Figure 2 shows results from a regression model in which simulations performed in iPSC-CMs, under 8 97 experimental conditions (described in Methods), are used to predict responses in adult myocytes. 98
However, some of the 8 protocols may provide partially redundant information, and it is generally 99 unrealistic to record from an individual cell under 8 separate conditions. Therefore, to prioritize efforts 100 and direct experimental design, we evaluated the contribution of each simulated condition to the 101 predictive strength of the cross-cell type model. First we examined iPSC-CM population distributions of 102 APD 90 ( Fig. 3A) and CaTA ( Fig. 3B ) under different experimental conditions. We observed that, compared 103
with the baseline distributions of spontaneously beating cells (black lines and shaded histograms), some 104 conditions caused minimal changes (e.g. 0.5 Hz pacing, orange histograms) whereas others caused more 105 dramatic shifts in the population distributions (e.g. 2 Hz pacing, blue, and increased extracellular [Na + ], 106 purple). Based on these results, we hypothesized that conditions which shift these distributions are 107 more informative and contribute more predictive power than those which cause minimal changes. 108
To test this hypothesis and identify the most informative simulation protocols, we constructed 109 regression models based on sequential inclusion ( conditions. With these two complementary approaches, we either included the protocol that led to the 111 greatest improvement in R 2 , or excluded the protocol that caused the smallest decrease in R 2 . The two 112 evaluation approaches led to similar results, and from these we concluded that the 3 most informative 113 simulation conditions (3-MOST protocols) were: 1) an increase in extracellular complementary information and improve prediction accuracy, we generated all 56 possible regression 118 models that include 3 simulation protocols chosen from the 8, and evaluated each model based on the 119 adjusted R 2 values for APD 90 (Fig. 3E ) and CaTA ( Fig. 3F ). Confirming the results of the inclusion and 120 exclusion approaches, we found that combinations with 2 or more protocols from the 3-MOST category 121 (purple bars) achieved higher R 2 values, compared with models that included 2 or more protocols from 122 3-LEAST (orange bars), or mixed combinations (blue bars). 123
Based on these results, our optimized model used in subsequent simulations was built from the three 124 most informative experimental protocols, in addition to spontaneous beating and 2 Hz pacing. The 125 optimized cross-cell type model achieved R 2 =0.903 for APD 90 and R 2 =0.967 for CaTA following five-fold 126 cross validation. 127 Distributions of adjusted R 2 values for APD 90 (E) and CaTA (F) of the 56 regression models that can be built by randomly choosing 3 protocols from the initial set of 8. Regression models that select 2 or more protocols from the 3-MOST list (purple) exhibit better predictive power than models that select 2 or more protocols from the 3-LEAST list (orange).
Cross-cell type predictions of ionic current blockade are accurate for both selective and nonselective 128
drugs 129
We next set out to test the ability of the optimized cross-cell type regression model to predict how adult 130 myocytes respond to additional ionic perturbations. These simulations were performed in 131 heterogeneous populations of iPSC-CMs and adult myocytes (100 cells in each group), which allowed us 132
to account for variability between myocytes and to estimate the precision of the predictions. Figs. 4A-D 133
show the simulated effects of I Kr and I CaL -blocking drugs over a range of concentrations corresponding to 134 5-55% channel block. Whether examining the change in APD 90 (panels A and C) or the change in CaTA 135 (panels B and D), the regression model prediction (purple) provides a much better estimate of the adult 136 myocyte response (gray) than does the change in APD 90 or CaTA observed directly from iPSC-CMs (cyan). 137
Figs. 4E and 4F show predicted effects of drugs that selectively inhibit 10 ion transport pathways (all 138 simulated at 50% block). With all drugs that cause substantial effects in adult myocytes, the cross cell 139 type predictions (purple) represent a much better prediction of adult myocyte effects (gray) than the 140 straightforward iPSC-CM recordings (cyan). 141
Simulations were also performed to predict the effects of nonselective drugs that inhibited multiple ion 142 transport pathways. For the 10 important ion transport pathways that were simulated (i.e. those in Fig.  143 4E), we posited 90 hypothetical drugs that blocked 2 of these pathways with different affinities. We 144 assumed that the IC 50 values for the primary and secondary targets differed by a factor of e (2.718), and 145
we simulated drug effects at the lower IC 50 such that the primary target was inhibited by 50% and the 146 secondary target was inhibited by 27%. Fig. 5 plots, on the abscissa, the percent change simulated in 147 adult myocytes of APD 90 (Fig. 5 , left) and CaTA (Fig. 5, right) . The ordinate represents the calculated 148 estimates of these values, taken either directly from spontaneously beating iPSC-CMs (cyan symbols) or 149 the cross-cell type regression model (purple symbols). Simulations were performed in heterogeneous 150 populations of 100 myocytes each, and mean values and population standard deviations are shown. 151 In each panel, the simulated iPSC-CM response with baseline spontaneous contraction is shown in cyan, the simulated adult myocyte response is shown in dark gray, and the regression model prediction is shown in purple. In all cases, simulations were performed with heterogeneous populations of 100 cells; symbols and error bars represent mean and standard deviation, respectively. (E, F) Simulated selective block (50%) of 10 ion transport pathways, with colors as described for panels A-D. Simulated drug-induced changes are shown as percent changes in APD 90 (E) and CaTA (F).
Since, with a perfect predictor, all points would lie on the line of identity, the cross-cell type model 152 clearly produces more accurate predictions of APD 90 and CaTA than the iPSC-CM recordings. Thus, the 153 cross-cell type regression model accurately predicts the response of adult myocytes to both selective 154 and nonselective drugs. 155
Figure 5. Responses to 90 hypothetical non-selective ion channel blockers
Simulations were performed in adult myocyte and iPSC-CM models of 90 hypothetical drugs that affected two ion transport pathways with different potencies. All simulations were performed in heterogeneous populations of 100 cells each, and mean ± standard deviation is shown. For drug effects on APD 90 (left) and CaTA (right), simulated adult myocyte responses (abscissa) are plotted versus estimated responses (ordinate) either directly from iPSC-CM simulations under spontaneous contraction (cyan filled symbols) or from crosscell type regression model predictions (purple empty symbols). Coefficient of determination (R 2 ) was calculated to demonstrate the predictive accuracy. For cross cell type predictions, R 2 =0.957 and 0.987 for APD 90 and CaTA, respectively. For iPSC-CM spontaneous responses, R 2 =-0.630 and 0.223 for APD 90 and CaTA, respectively.
Cross-cell type regression approaches are generalizable for multiple cell types 156
To test whether the cross-cell type approach was generalizable, we built and tested additional cross-cell 157 type regression using mechanistic models describing ventricular myocytes from additional species. 158
Specifically, using models of rabbit ( in two cells, cross-cell type regression models can correct for the mismatch. For example, 50% block of 171 NCX causes little change to APs in guinea pig myocytes (Fig. 6C , left) but shortens APs in rabbit myocytes 172 ( Fig. 6C, right) . A cross-cell type regression model built from guinea pig simulations can predict the 173 effects in rabbit, and vice-versa, as quantified in Fig. 6E . As another example, 50% block of SERCA activity 174
reduced CaTA in guinea pig myocytes ( Fig. 6D , left) while causing minimal effects in rabbit myocytes ( Fig.  175 6D, right), effects that are accurately captured by the cross-cell type models (Fig. 6F) . 176 
Differential drug responses in diseased versus healthy cells can be predicted 177
In a final step, we determined whether cross-cell type regression could predict differences in drug 178 responses between healthy and diseased cells. Based on published results (Gomez et al., 2014) myocytes (bottom), using the respective regression matrices for prediction. As an example, these 188 models can successfully predict the differential effects on CaTs seen in healthy and HF cells when NCX is 189 blocked by 40%. This perturbation causes a dramatic increase in CaTA in healthy myocytes (Fig. 7C) , but 190 only a small increase in HF myocytes (Fig. 7D) , effects that are well predicted by the two regression 191 models (compare symbols with solid lines). Quantification of these effects in Fig. 7E verifies the 
DISCUSSION 197
In this study we have described a methodology combining mechanistic modeling with statistical analyses 198 to quantitatively translate drug effects across cell types. To develop a predictive model, we first ran 199 simulations with populations of mechanistic cardiac myocyte models. We then performed multivariable 200 regression on the population simulation results --this regression model allowed us to translate drug 201 responses from iPSC-CMs to human adult myocytes. The model was highly predictive, with cross-202 validation R 2 values of 0.906 and 0.964 for APD and CaTA, respectively (Fig. 2B) . Moreover, when 203 selective and non-selective blockers of several important ion transport pathways were simulated in 204 iPSC-CMs under multiple conditions, the cross-cell type model predicted adult myocyte responses with 205 quantitative precision. These predictions greatly outperformed a naive approach in which adult myocyte 206 drug responses were assumed to be identical to those seen in iPSC-CMs ( Figs. 4 and 5) . Importantly, 207 accurate predictions were also obtained when the strategy was applied to ventricular myocyte models 208 from additional species or to a model of diseased human myocytes ( Figs. 6 and 7) , demonstrating the 209 general utility of the concept. 210
This novel cross-cell type regression model can address, in a quantitatively rigorous way, differences 211 between an experimental model and the system that is ultimately of interest. The prediction model 212 developed in this study possesses tremendous potential as a practical tool for toxicity testing in drug 213 development, and the overall strategy, which can readily be applied to other fields of research, offers a 214 roadmap for overcoming the limitations that are inherent to experimental models. 215
The potential impact of cross-cell type modeling in drug development 216
Human iPSC-CMs hold considerable promise as a screening platform for assessing how drugs cause 217 either beneficial or deleterious cardiac effects. The application that is most well-developed at present is 218 the use of iPSC-CMs for assessment of drug-induced arrhythmia risk. Specifically, experimental studies 219 with iPSC-CMs are a major pillar of the Comprehensive in vitro Proarrhythmia Assay, or CiPA, a 220 public/private partnership involving the Food and Drug Administration, several pharmaceutical 221 companies, and academic research groups (Cavero & Holzgrefe, 2014, Colatsky et al., 2016, Fermini et  222  al., 2016, Gintant et al., 2016, Sager et al., 2014) . The goal of CiPA is to replace current pro-arrhythmia 223 tests, which can be non-specific, with a fully in vitro assay involving ionic current measurements, 224 mathematical modeling, and iPSC-CM experiments. A worrisome and unresolved issue within CiPA, 225 however, is the fact that iPSC-CM physiology differs from that of adult myocytes. In general, iPSC-CMs 226 are considered to possess an immature phenotype that resembles fetal heart cells more than adult 227 heart cells (Li et al., 2013, van den Heuvel et al., 2014) . This is seen both structurally, in the fact that 228 iPSC-CMs lack transverse tubules and a regular organization of sarcomeres (Bedada et al., 2016) , and 229
functionally, in features such as the contribution of SR Ca 2+ release to Ca 2+ transients (Li et al., 2013) and 230 the densities of particular K + channels (Bett et al., 2013) . 231
Because of these physiological differences, drug responses observed in iPSC-CMs and adult myocytes 232 are also expected to differ (Ma et al., 2011, Mehta et al., 2013, Paci et al., 2015, Sheng et al., 2012) . 233 The sensitivity analysis shown in Figs. 1E and 1F illustrates these differences by quantifying how changes 234 in any of the shared ion transport pathways influence APD and CaTA in the two model cells. For some 235 effects, such as changes in APD resulting from altered I Kr , the two models are largely convergent. For 236 others, however, such as alterations in I CaL , dramatic differences are observed. Given that the L-type Ca 2+ 237 channel is a major ion channel in the CiPA initiative, these discrepancies present a potentially serious 238 problem for the use of iPSC-CMs in drug development. The cross-cell type regression approach 239 described in this study illustrates how these limitations may be overcome. Instead of approximating 240 drug effects directly --i.e. assuming that drug-induced physiological changes are identical in adult 241 myocytes and iPSC-CMs --a combination of mechanistic modeling and statistical analyses can be used to 242 develop cross-cell type prediction models, and these in turn can correct for mismatches and provide 243 more accurate predictions. 244
Of course, another approach to addressing differences between iPSC-CMs and adult myocytes is to 245 improve the iPSC-CM experimental model such that the cell types become more similar. Indeed, recent 246 years have seen many advances to optimize differentiation and produce more mature iPSC-CMs (Herron  247  et al., 2016, Kadota et al., 2017, Ribeiro et al., 2015) . We note, however, that our strategy is not in 248 competition with these important efforts, instead it is a complementary approach that is likely to 249 become even more urgently needed as maturation methods develop. For one thing, even if a truly 250 optimal iPSC-CM maturation protocol can eventually be identified, cells will almost certainly continue to 251 exhibit some differences with adult cells, and methods to understand these differences quantitatively 252
will still be required. Additionally, the next several years are likely to see a proliferation of alternative 253 methods rather than rapid agreement on a protocol of choice. In this scenario, the field will require 254 ways to translate effects between different iPSC-CM production methods. Finally, a close approximation 255 of the healthy adult ventricular myocyte is not the only cell type that is needed in drug development. 256
Because diseased hearts and healthy hearts may respond differently to the same drugs, we also require 257 methods to understand how therapeutics may affect particular patient populations. Fig. 7 illustrates  258 how, once appropriate regression models have been developed, recordings obtained in a single iPSC-CM 259 preparation can simultaneously predict drug effects in both healthy and failing adult myocytes. Thus, 260 efforts to improve the iPSC-CM experimental model will become more powerful when they are coupled 261 to modeling approaches that can quantitatively synthesize results across different preparations. 262
Practical considerations in employing cross-cell type predictions 263
In addition to developing a model that would be useful for drug development, we also addressed 264 practical considerations required to implement such cross-cell type approach. One of the fundamental 265 principles underlying our model is that studying multiple experimental conditions provides additional 266 information. In other words, simulating only a population of spontaneously contracting iPSC-CMs might 267 not be sufficient to accurately predict drug responses in adult myocytes, but if the same iPSC-CMs are 268 simulated under different pacing protocols, different ionic conditions, etc., then an accurate regression 269 model can be generated. In practical terms, however, it is not always feasible to examine individual cells 270 under a wide range of experimental conditions. Accordingly, we identified the most informative 271 simulation conditions in iPSC-CMs for accurate predictions of adult myocyte responses (Fig. 3) . This 272 analysis ranked experimental protocols from the most to the least informative, based on the 273 contribution made by each to the regression model accuracy. An interesting result to arise from this 274 analysis was that altering extracellular ion concentrations appears to be more useful than electrical 275 pacing, a prediction that remains to be tested. In broader terms, however, this shows how the approach 276
we have employed can inform experimental design, by identifying protocols that provide novel 277 information. 278
In implementing an approach such as we have outlined here, an additional practical consideration that 279 must be addressed is the mathematical model of the iPSC-CM. Although many alternative mathematical 280 models of animal myocytes (Bondarenko, 2014, Devenyi & Sobie, 2016, Hund & Rudy, 2004) and human 281 adult ventricular myocytes (Grandi et al., 2010, ten Tusscher & Panfilov, 2006) have been published, the 282 Paci et al model (Paci et al., 2013) remains, at the present time, the only model of the iPSC-CM. The 283 preferred approach to modeling iPSC-CM physiology will certainly be modified as additional data 284 become available, and as iPSC-CMs developed under particular conditions become more completely 285 characterized. To facilitate the future development of model improvements, an efficient and valuable 286 approach is to choose parameters that match physiological responses (e.g. APs and CaTs) not only under 287 baseline conditions, but in response to perturbations such as augmenting or inhibiting particular ionic 288 currents (Devenyi et al., 2017, Groenendaal et al., 2015) . Compared with the alternative strategy of 289 characterizing each important ion transport mechanism in every cell type of interest (i.e. fitting models 290
to voltage clamp data), this approach offers the possibility of more rapidly tuning a model to 291 recapitulate experimental data, once the general model structure (i.e. which ion transport mechanisms 292 should be included) is understood (Krogh-Madsen et al., 2016) . Importantly, these recent studies 293 provide a guide for how to continually improve the cross-cell type approach as additional data are 294 obtained and models of the relevant cell types become more advanced. 295
The cross-cell type concept can be extended to additional contexts 296
Results such as those shown in Figs. 6 and 7 can initially seem quite surprising: if blocking a particular 297 pathway causes minimal effects in one cell type, how can the model successfully reproduce more 298 dramatic effects in another cell type? The answer to this question arises from two important aspects of 299 the cross-cell type regression approach: 1) variability is universally imposed on all the major ion 300 transport pathways when generating the heterogeneous cell populations; and 2) a wide range of 301 simulation results, obtained under multiple experimental conditions, are recorded. These ensure that 302 the underlying statistical associations are robust enough to make accurate predictions, even in cases 303
where obvious differences exist between the source and target cells. Put another way, APD in the adult 304 human myocyte is not simply a function of APD in the iPSC-CM; instead this output depends on an 305 appropriately weighted average of many physiological metrics that can be measured in iPSC-CMs. Our 306 approach therefore advocates for considering all relevant information systematically, and synthesizing 307 based on rigorous statistical analysis, rather than necessarily focusing on particular measurements that 308 are deemed to be most important. 309
Beyond being a practically useful platform, the cross-cell type regression provides information for future 310 mechanistic studies. Although the extension to rabbit and guinea pig ventricular myocyte models 311 demonstrated that the concept is generalizable (Fig 6) , it should be noted that the prediction accuracy 312 was not identical for all models generated. For instance, the worst-performing model, the translation 313 from rabbit to guinea pig myocytes ( Fig S3) , probably reflects important differences between the two 314 cell types, and these studies can guide future efforts to uncover these mechanistic differences. 315
More broadly, however, this extension to additional cardiac myocyte models suggests ways that the 316 concept can be further generalized and expanded. The number of cell types seen in the nervous system, 317
for instance, dwarfs what is observed in the heart. However, because different types of neurons employ 318 many of the same channels and receptors to shape their behaviors, an approach such as ours should be 319 feasible for predicting differences. Similarly, the pathways that control processes such as cell division 320
and apoptosis are largely shared between different cell types, although the ways that cells respond to 321 physiological or pharmacological stimuli can be extremely different. For issues such as these, where 322 robust mathematical models already exist (Albeck et al., 2008, Ciarleglio et al., 2015, Csikasz-Nagy et  323  al., 2006, Drion et al., 2015, Qu et al., 2003, Rinberg et al., 2013, Shin et al., 2014, Sible & Tyson, 2007) , 324 a cross-cell type approach such as we have outlined can be used to predict how behaviors observed in 325 one cell type may or may not translate into a related cell type. 326
Study Limitations 327
Although the results presented in this study are encouraging and provide confidence that the concept 328
can be of practical use, several limitations should be noted. First, in generating the heterogeneous 329 populations, we only varied model parameters controlling ionic current magnitudes, leaving the channel 330 kinetics unaltered. As a result, we could only simulate drug effects through a simple pore block model. 331
Many drugs, however, bind to ion channels in a state-dependent manner, producing effects that our 332 approach could potentially fail to predict. These complexities could be included through the use of more 333 complex Markov models, which have been developed for many critical channels (Li et al., 2017, Moreno  334  et al., 2011, Silva & Rudy, 2005) . Second, although the regression model performed extremely well with 335 simulated data, the experimental validity of these predictions remains to be tested. Although the 336 ultimate goal of many cardiac experimental models is to predict behaviors in adult human hearts and 337 myocytes, the difficulty of obtaining such tissue for experiments precluded the use of such tests in this 338 study. However, alternative methods for testing the robustness of the concept do exist, for instance by 339 testing the physiological responses to drug treatments across different iPSC-CM preparations. Studies 340 have shown, for instance, that physiological differences exist between iPSC-CMs purchased from 341 alternative vendors (Blinova et al., 2017, Lu et al., 2017) . These alternative iPSC-CM variants may prove 342 a useful platform for experimentally testing this approach, and the results obtained in such a 343 comparison may help to drive convergence towards a more optimal iPSC-CM experimental model. 344
Conclusions 345
We developed a novel methodology that serves to translate drug effects across cell types with 346 quantitative accuracy, an approach that is likely to be widely useful for addressing differences between 347 experimental models and target systems of interest. Not only is the initial test case we presented, the 348 translation from iPSC-CMs to human adult myocytes, potentially of practical use during toxicity testing 349
to identify pro-arrhythmic drugs, the approach we have outlined can be used to streamline and optimize 350 experimental design. Most important, the methodology we have outlined can easily be applied to other 351 fields in which mechanistic models are well-developed, potentially greatly increasing the impact of the 352 concept and approach. 353
354

ACKNOWLEDGEMENTS 355
This work was supported by the National Institutes of Health (U01 HL136297 to EAS) and the American 356
Heart Association Predoctoral Fellowship Award (17PRE33670541 to JQXG). 357
358
COMPETING INTERESTS 359
The authors declare no competing interests. 360
361
MATERIALS AND METHODS 362
Mathematical models 363 We developed regression models to predict effects across cell types by using simulations performed 364
with 4 prior work (Gomez et al., 2014) , to reproduce molecular and physiological changes observed in heart 371 failure (HF). Parameter modifications made to produce the O'Hara HF variant are shown in 372 Supplementary Table S5 . 373
Each model consists of a system of ordinary differential equations --models were implemented in 374
MATLAB version R2016b (The MathWorks, Natick, MA), a solver for stiff systems (ode15s) was used for 375 numerical integration, and simulations were performed in a Windows 10 environment. 376
Simulations of heterogeneous model populations 377
To generate heterogeneous populations of models, parameters controlling maximal rates of ion 378 transport were multiplied by scale factors randomly selected from log-normal distributions. Randomly 379 varied model parameters included: fast Na + current (G Na ), inward rectifier K + current (G K1 ), rapid and slow 380 delayed rectifier K + currents (G Kr , G Ks ), transient outward K + current (G to ), L-type Ca 2+ current (G CaL ), Na + -381 Ca 2+ exchanger (K NCX ), Na + -K + pump (K NaK ), sarcolemmal Ca 2+ pump (G pCa ), background Na + and Ca 2+ 382 currents (G bNa , G bCa ), SR Ca 2+ release flux through ryanodine receptors (K RyR ), and SR Ca 2+ uptake via 383 SERCA pumps (K SERCA ). Baseline values for these model parameters can be found in Supplementary  384 Tables S1-S2. As a result of this scaling, each individual cell in the population has a distinct profile of ion 385 channel/pump/transporter expression levels. 386
Scale factors were log-normally distributed such that log-transformed values had a mean of zero and a 387 standard deviation of 0.2624. As a result, 95% of the cells in the populations had expression levels 388 ranging between 60-167% of control values. The same set of scale factors was applied to the two cell 389 types used to construct cross-cell type regression models. Simulations were performed for every cell in 390 the population, and features (indicated in Fig. 2, inset) were extracted from the action potential (AP) and 391 calcium transient (CaT) waveforms. 392
Simulation protocols 393
Cells that do not contract spontaneously (adult human, rabbit, and guinea pig myocytes) were allowed 394 to rest for 300 s, then electrically stimulated at 1 Hz for 120 s. The last AP and CaT in the sequence were 395 recorded. For spontaneously contracting iPSC-CMs, the last AP and CaT in a 120 s simulation period 396
were recorded. Additional experimental protocols were simulated in iPSC-CMs, rabbit myocytes, and 397 guinea pig myocytes. These included: 1) electrical pacing at 0.5 Hz and 2 Hz for 120 s; 2) increasing and 398 decreasing extracellular [Ca 2+ ] (baseline =1.8 mM, high = 3.0 mM, low = 0.9 mM), 3) increasing and 399 decreasing extracellular [Na + ] (baseline = 151 mM, high = 300 mM, low = 70 mM); and 4) increasing and 400 decreasing extracellular [K + ] (baseline = 5.4 mM, high = 10 mM, low = 3 mM). For the protocols that 401 varied extracellular ion concentrations, guinea pig and rabbit myocytes were electrically stimulated 402
whereas spontaneously contracting iPSC-CMs were simulated. We chose these protocols because of the 403 ease with which they can be implemented experimentally. 404
Construction and validation of cross-cell type models 405
Partial Least Squares Regression (PLSR) (Abdi & Williams, 2013, Geladi & Kowalski, 1986, Kreeger, 2013 ) 406 was used to quantitatively relate physiological features in one cell type (the source cell) to those in 407 another cell type (the target cell). To develop these regression models, features quantified from AP and 408
CaT waveforms were placed into matrices. The "input" matrix consisted of features simulated under 409 multiple conditions from the cells in the source population (e.g. iPSC-CM) whereas the "output" matrix 410 consisted of features in the target cells (e.g. adult human myocytes). Each row in these matrices 411
corresponded to a different cell in the population; each column corresponded to a different simulated 412 feature. PLSR was then applied to derive a matrix, B cross , that translates from one cell type to another 413 and can subsequently be used for predictions. For instance, if the effects of a drug perturbation were 414 recorded in iPSC-CMs, the matrix B cross could be used to predict the effects of the same drug in adult 415
myocytes. 416
During model construction, we performed cross-validation to evaluate the prediction accuracy. For 417 example, to perform five-fold cross validation, populations of 600 cells were divided into five subgroups 418 of 120 cells each. Each regression matrix B cross derived from 4 subgroups (480 cells) was then used to 419 predict behavior in the remaining subgroup. The performance of the cross-cell type model was 420 evaluated using Predicted Residual Sum of Squares, or PRESS (see Supplementary Methods for details). 421 PLSR is an iterative approach that requires using weighted combinations of input variables (similar to 422 principal components). PLSR is well-suited for datasets in which the columns in the input matrix are 423 correlated; however, it is important to terminate the iterative PLSR algorithm at the appropriate time to 424 avoid overfitting (Hawkins, 2004 , Tetko et al., 1995 . As described in more detail in Supplemental 425
Methods, we chose the number of components of the PLSR model by iteratively determining the 426 smallest number of components that minimized PRESS while simultaneously achieving a high R 2 value. 427
Identification of the most informative and least informative experimental conditions 428
To determine whether cross-cell type modeling was feasible, we initially constructed a model using 429 simulated results obtained under many experimental conditions. To make this model more suitable for 430 experimental testing, we determined the most informative experimental conditions using sequential 431 inclusion and exclusion methods. First, although we initially simulated 10 experimental conditions (see 432 above), we found that under some conditions, more than 25% of the cells in the population exhibited 433 abnormal dynamics (e.g. afterdepolarizations, failure to repolarize). These were excluded from the 434 determination of the most informative conditions. 435
For the sequential inclusion method, we generated PLSR models using each of the 8 experimental 436
conditions individually, and selected the one with the highest average R 2 with 5-fold cross validation. We 437 then added each of the 7 remaining conditions in turn, and selected the one that caused the largest 438 increase in R 2 . This process continued until all 8 experimental conditions had been ranked. Similar 439 criteria were used for the sequential exclusion method, during which we started with all 8 conditions, 440 excluded one condition at a time, then rejected the one that whose exclusion caused the smallest 441 decrease in R 2 value. 442
Simulations of selective and non-selective drugs in heterogeneous populations 443 We simulated selective and non-selective blockers of ion transport pathways by scaling the model 444 parameters controlling the magnitudes of ionic current or flux. For example, when simulating selective 445 blockade of I Kr by 50% percent, we scaled the conductance G Kr to 50% of its control value. For details of 446 all tested ion transport pathways, see Supplementary Tables S3-S4 . 447
The 90 non-selective hypothetical drugs were designed such that, of the 10 important ion transport 448 pathways (as tested with selective blockers in Fig. 4 ), each hypothetical drug targets 2 of the 10 449 pathways with different affinities, and the IC 50 values for primary and secondary targets differ by a 450
factor of e (2.718). To simulate the effects of 90 hypothetical drugs, we scaled the model parameters 451
controlling the maximal magnitude of ion current/flux for primary and secondary targets according to 452 the equation: 453 = 50 50 + For the 90 hypothetical non-selective blockers, we simulated drug effects at the lower IC 50 , a 454 concentration at which the primary target was inhibited by 50% and the secondary target was inhibited 455 by 27%. 456 457
